AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
Related Posts
Canadians keep Liberal Party and Mark Carney in power as country digs in on Trump’s trade war
President Donald Trump injected himself into the race with his tariffs on Canadian imports and repeatedly saying Canada should become the 51st U.S. state.
Tesla inks first deal to build China’s largest grid-scale battery power plant
The U.S. company posted on the Chinese social media service Weibo that the project would be the largest of its kind in China when completed.
Trump Media shares gain 10% in after-hours trading as voting in heated presidential election nears end
Shares in the former president’s media company jumped after the company revealed a surprise earnings statement on Election Day.